

09/602,800

perdy.

filing date = 6/23/00  
prior. - 6/25/99

6/14/01, B15  
6/19/01, B15

inventor AGUS, SCHER & SLLWICKOWSKI

In the Claims:

1. (Currently amended) A method of treating androgen independent prostate cancer in a human comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2, and blocks ligand activation of an ErbB receptor substantially more effectively than humanized monoclonal antibody huMAb4D5-8 (HERCEPTIN®), and blocks by 50% or greater binding of monoclonal antibody 2C4 (ATCC HB12697) to ErbB2.

2. (Canceled).

3. (Original) The method of claim 1 wherein the antibody blocks TGF- $\alpha$  activation of mitogen-activated protein kinase (MAPK).

4. (Earlier presented) The method of claim 1 wherein the antibody blocks formation of an ErbB hetero-oligomer.

5. (Previously amended) The method of claim 1 wherein the antibody comprises monoclonal antibody 2C4 (ATCC HB12697) or a humanized form thereof that binds to the same epitope as the monoclonal antibody 2C4 (ATCC HB12697).

6. (Original) The method of claim 1 wherein the antibody is an antibody fragment.

7. (Original) The method of claim 6 wherein the antibody fragment is a Fab fragment.

8. (Original) The method of claim 1 wherein the antibody is not conjugated with a cytotoxic agent.

9. (Original) The method of claim 6 wherein the antibody fragment is not conjugated with a cytotoxic agent.

10.-21. (Canceled)

22. (Currently amended) A method of treating androgen independent prostate cancer in a human comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2, blocks ligand activation of an ErbB receptor, blocks by 50% or greater binding of monoclonal antibody 2C4 (ATCC HB12697) to ErbB2, and blocks TGF- $\alpha$  activation of mitogen activated protein kinase (MAPK).

23. (Previously amended) The method of claim 22 wherein the antibody comprises monoclonal antibody 2C4 (ATCC HB12697) or a humanized form thereof that binds to the same epitope as the monoclonal antibody 2C4 (ATCC HB12697).

11 ~~24~~ (Previously presented)  
an antibody fragment.

9  
The method of claim ~~22~~ wherein the antibody is

12 ~~25~~ (Previously presented)  
fragment is a Fab fragment.

11  
The method of claim ~~24~~ wherein the antibody

14 26. (Previously presented)  
fragment is not conjugated with a cytotoxic agent.

9  
The method of claim ~~22~~ wherein the antibody

13 27. (Previously presented)  
fragment is not conjugated with a cytotoxic agent.

11  
The method of claim ~~24~~ wherein the antibody

28.-31. (Canceled)